Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma.
Adolescent
Adult
Aged
Antineoplastic Agents, Immunological
/ pharmacology
Biomarkers, Tumor
Female
Humans
Immunotherapy, Adoptive
/ methods
Lymphocytes, Tumor-Infiltrating
/ immunology
Male
Melanoma
/ immunology
Middle Aged
Neoplasm Metastasis
Neoplasm Staging
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Young Adult
Adoptive cell therapy
PD-1 antibody therapy
ipilimumab
metastatic melanoma
tumor-infiltrating lymphocyte therapy
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
06
08
2019
revised:
16
08
2019
accepted:
17
08
2019
entrez:
15
9
2019
pubmed:
15
9
2019
medline:
27
9
2019
Statut:
ppublish
Résumé
Adoptive transfer of tumor-infiltrating lymphocytes (TILs) combined with non-myeloablative chemotherapy (NMA) has been shown to prolong survival in patients with metastatic disease. Tissue harvesting was performed form a variety of sites. TILs were isolated, expanded and infused with bolus high-dose IL-2. Between 2008 and 2018, 242 lesions were resected for TILs harvesting from a range of sites form 196 patients without mortality and with minimal morbidity. Of those harvested, 75 were unable to complete therapy because of clinical deterioration during the wait period. Of 121 evaluable treated patients, there was no effect of metastatic site biopsied on the mean fold TIL expansion. Those receiving prior ipilimumab had a higher TIL fold expansion but a lower TIL fold expansion than those exposed to anti-PD1 therapy. Harvesting may be safely performed with successful TIL expansion from most sites. Prior check point inhibitory immunotherapy may potentially influence TIL fold expansion.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
Adoptive transfer of tumor-infiltrating lymphocytes (TILs) combined with non-myeloablative chemotherapy (NMA) has been shown to prolong survival in patients with metastatic disease.
MATERIALS AND METHODS
METHODS
Tissue harvesting was performed form a variety of sites. TILs were isolated, expanded and infused with bolus high-dose IL-2.
RESULTS
RESULTS
Between 2008 and 2018, 242 lesions were resected for TILs harvesting from a range of sites form 196 patients without mortality and with minimal morbidity. Of those harvested, 75 were unable to complete therapy because of clinical deterioration during the wait period. Of 121 evaluable treated patients, there was no effect of metastatic site biopsied on the mean fold TIL expansion. Those receiving prior ipilimumab had a higher TIL fold expansion but a lower TIL fold expansion than those exposed to anti-PD1 therapy.
CONCLUSION
CONCLUSIONS
Harvesting may be safely performed with successful TIL expansion from most sites. Prior check point inhibitory immunotherapy may potentially influence TIL fold expansion.
Identifiants
pubmed: 31519606
pii: 39/9/4995
doi: 10.21873/anticanres.13689
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Biomarkers, Tumor
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4995-5001Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.